Non-Alcoholic Steatohepatitis Pipeline Analysis: Overview, Pipeline Drugs, and Therapeutics Assessment

The key companies such as Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others are involved in developing drugs for Non-Alcoholic Steatohepatitis.

The Non-Alcoholic Steatohepatitis report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The report also highlights the unmet needs concerning the development of Non-Alcoholic Steatohepatitis. 

Some of the key highlights of the Non-Alcoholic Steatohepatitis Pipeline Report–

• Resmetirom (MGL-3196) is a first-in-class, orally-administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist.
• 348 patients were screened and 84 were randomly assigned to resmethrin and 41 to placebo at 18 sites in the USA.
• Key Players Involved in the Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others.

Request for Sample @ Non-Alcoholic Steatohepatitis Pipeline Insights

Non-Alcoholic Steatohepatitis Overview

Non-Alcoholic Steatohepatitis, liver inflammation, and damage caused by a buildup of fat in the liver. Nonalcoholic fatty liver disease (NAFLD) is an umbrella term for a range of liver conditions. The more severe form of NAFLD is called nonalcoholic steatohepatitis (NASH).

NASH Emerging Therapy: Drug Profile

MGL-3196: Madrigal Pharmaceuticals

Resmetirom neither suppresses the central thyroid axis nor THR-α effects on heart rate or bone, and it reduces elevated liver enzymes in NASH patients. Madrigal Pharmaceuticals plans to submit a marketing approval application in Non-alcoholic steatohepatitis to the US FDA.

Know More Information @ NASH Pipeline Drugs

Key Pipeline Therapies along with companies

• MGL-3196: Madrigal Pharmaceuticals
•  Oltipraz: Pharmaking
• TERN-101:Terns Pharmaceuticals
• EYP001: ENYO Pharma
• ZSP-1601: Guangdong Zhongsheng Pharmaceutical
• ALN-HSD: Alnylam Pharmaceuticals
• AZF-2693: AstraZeneca

NASH Therapeutics Assessment

By Product Type

• Mono
• Combination

By Stage

• Discovery 
• Pre-clinical
• IND
• Phase I
• Phase II
• Phase III
• Pre-registration

By Route of Administration

• Intravenous
• Inhalation
• Oral
• Subcutaneous 

By Molecule Type 

• Small Molecule 
• Gene Therapy
• Stem Cell Therapy

By Mechanism of Action

• Protease Inhibitors
• Immunomodulatory

By Targets

• Protease 
• Immune System

Contact Here for More Information @ NASH Pipeline Assessment

Scope of NASH Pipeline Report

• Coverage- Global
• Key Market Players-Madrigal Pharmaceuticals, Pharmaking, Terns Pharmaceuticals, ENYO Pharma, Guangdong Zhongsheng Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca, and many others.
• Key NASH Pipeline Therapies- MGL-3196, Oltipraz, TERN-101, EYP001, ZSP-1601, ALN-HSD, AZF-2693, and many others

Following is the Table of Content of the NASH Pipeline Report

Know more of what’s covered in the NASH Pipeline Assessment report

Key Questions Answered in the NASH report–

• What are the current options for Non-Alcoholic Steatohepatitis (NASH) treatment?
• How many companies are developing therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)? 
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
• How many Non-Alcoholic Steatohepatitis (NASH) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Non-Alcoholic Steatohepatitis (NASH)?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Non-Alcoholic Steatohepatitis (NASH) market? 
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)?  
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Non-Alcoholic Steatohepatitis (NASH) therapies? 
• What are the clinical studies going on for Non-Alcoholic Steatohepatitis (NASH) and their status?
• What are the results of the clinical studies and their safety and efficacy? 
• What are the key designations that have been granted for the emerging therapies for Non-Alcoholic Steatohepatitis (NASH)? 
• How many patents are granted and pending for the emerging therapies for the treatment of Non-Alcoholic Steatohepatitis (NASH)? 

Request for demo @ NASH Pipeline and get a walk-through of our report

Related Reports

Uncontrolled Bleeding Market

DelveInsight’ s Uncontrolled Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.

Post-Operative Nausea & Vomiting  Market 

DelveInsight’ s Postoperative Nausea & Vomiting Market Insights, Epidemiology and Market Forecast – 2030 report.

Heavy Menstrual Bleeding  Market

DelveInsight’ s Heavy Menstrual Bleeding Market Insights, Epidemiology and Market Forecast – 2030 report.

Visit on our blog section-

• Bleeding Disorders Therapeutics Market
• Gastroparesis Market Size | Gastroparesis Market | DelveInsight 

About DelveInsight

DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.

Contact Information:

Shruti Thakur
[email protected]